EIAS is a condition characterized by a clear history of exogenous insulin administration, in the absence of exposure to sulfhydryl-containing drugs or underlying autoimmune diseases, and with exclusion of insulinoma, type B insulin resistance, and other causes of hypoglycemia. The gene discussed is INS; the disease is pancreatic insulinoma.